HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PRDM16
PR/SET domain 16
Chromosome 1 Β· 1p36.32
NCBI Gene: 63976Ensembl: ENSG00000142611.17HGNC: HGNC:14000UniProt: Q9HAZ2
110PubMed Papers
22Diseases
0Drugs
16Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedTranscription Factor
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
DNA-binding transcription repressor activity, RNA polymerase II-specificDNA-binding transcription factor bindingnegative regulation of DNA-templated transcriptionpositive regulation of DNA-templated transcriptionleft ventricular noncompactioncardiomyopathy, dilated, 1LLdilated cardiomyopathyHeadache
✦AI Summary

PRDM16 (PR/SET domain 16) is a transcriptional regulator that functions as both a transcriptional activator and repressor depending on cellular context 1. The protein plays critical roles in adipose tissue biology, particularly in brown and beige adipocyte differentiation and thermogenesis. PRDM16 controls adipose tissue plasticity by regulating metabolic programs - it promotes white adipose tissue beiging and brown adipose tissue thermogenesis through activation of UCP1 expression 23. The protein also secretes Ξ²-hydroxybutyrate, a metabolite that blocks fibrogenesis and facilitates beige adipogenesis 4. In immune function, PRDM16 is essential for the development of tolerizing dendritic cells (tolDCs) that induce regulatory T cells specific for food and microbiota antigens, playing a crucial role in oral tolerance 1. Additionally, PRDM16 provides cytoprotection by suppressing ferroptosis through regulation of the NRF2/GPX4 axis, protecting against sepsis-induced acute kidney injury 5. Clinically, PRDM16 haploinsufficiency is associated with 1p36 deletion syndrome phenotypes 6, and vector insertions at the PRDM16 locus have been linked to hematologic malignancies in gene therapy patients 7.

Sources cited
1
PRDM16 functions as a transcriptional regulator and is essential for development of tolerizing dendritic cells that induce food and microbiota tolerance
PMID: 40228524
2
PRDM16 controls PPARΞ³ activity homeostasis and promotes adipose tissue plasticity through white adipose tissue beiging and brown adipose tissue thermogenesis
PMID: 38332049
3
PRDM16 is a key regulator of subcutaneous white adipose tissue beiging that supports skin repair
PMID: 38838641
4
PRDM16-expressing adipose cells secrete Ξ²-hydroxybutyrate metabolite that controls beige fat remodeling
PMID: 31155495
5
PRDM16 suppresses ferroptosis and protects against sepsis-induced acute kidney injury by targeting the NRF2/GPX4 axis
PMID: 39549609
6
PRDM16 is implicated in 1p36 deletion syndrome phenotypes
PMID: 26345236
7
Lentiviral vector insertions at PRDM16 locus are associated with hematologic cancer development in gene therapy patients
PMID: 39383458
Disease Associationsβ“˜22
left ventricular noncompactionOpen Targets
0.70Moderate
cardiomyopathy, dilated, 1LLOpen Targets
0.69Moderate
dilated cardiomyopathyOpen Targets
0.58Moderate
HeadacheOpen Targets
0.51Moderate
coronary artery diseaseOpen Targets
0.50Moderate
migraine disorderOpen Targets
0.49Moderate
genetic disorderOpen Targets
0.47Moderate
Left ventricular noncompaction cardiomyopathyOpen Targets
0.47Moderate
open-angle glaucomaOpen Targets
0.46Moderate
heart diseaseOpen Targets
0.42Moderate
Intrahepatic cholestasis of pregnancyOpen Targets
0.41Moderate
headache disorderOpen Targets
0.40Moderate
hypertensionOpen Targets
0.40Moderate
coronary atherosclerosisOpen Targets
0.39Weak
alcohol drinkingOpen Targets
0.39Weak
esophageal adenocarcinomaOpen Targets
0.38Weak
nervous system diseaseOpen Targets
0.38Weak
smoking initiationOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.37Weak
kidney neoplasmOpen Targets
0.37Weak
Cardiomyopathy, dilated, 1LLUniProt
Left ventricular non-compaction 8UniProt
Pathogenic Variants16
NM_022114.4(PRDM16):c.1459del (p.Glu487fs)Pathogenic
not provided|Left ventricular noncompaction 8
β˜…β˜…β˜†β˜†2025β†’ Residue 487
NM_022114.4(PRDM16):c.1573dup (p.Arg525fs)Pathogenic
Left ventricular noncompaction 8|not provided|Left ventricular noncompaction cardiomyopathy
β˜…β˜…β˜†β˜†2025β†’ Residue 525
NM_022114.4(PRDM16):c.885-1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_022114.4(PRDM16):c.676+2T>CPathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_022114.4(PRDM16):c.2861+1G>TLikely pathogenic
Left ventricular noncompaction 8
β˜…β˜†β˜†β˜†2024
NM_022114.4(PRDM16):c.2595dup (p.Ile866fs)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 866
NM_022114.4(PRDM16):c.559C>T (p.Gln187Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2023β†’ Residue 187
NM_022114.4(PRDM16):c.3142del (p.Leu1048fs)Likely pathogenic
Left ventricular noncompaction 8|PRDM16-related congenital heart disease
β˜…β˜†β˜†β˜†2023β†’ Residue 1048
NM_022114.4(PRDM16):c.2434del (p.Arg812fs)Likely pathogenic
Left ventricular noncompaction 8
β˜…β˜†β˜†β˜†2021β†’ Residue 812
NM_022114.4(PRDM16):c.534C>A (p.Cys178Ter)Pathogenic
Left ventricular noncompaction 8
β˜…β˜†β˜†β˜†2020β†’ Residue 178
NM_022114.4(PRDM16):c.2134C>T (p.Gln712Ter)Likely pathogenic
Left ventricular noncompaction 8
β˜…β˜†β˜†β˜†2018β†’ Residue 712
NM_022114.4(PRDM16):c.1989del (p.Glu664fs)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2018β†’ Residue 664
NM_022114.4(PRDM16):c.827del (p.Gly276fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2017β†’ Residue 276
NM_022114.4(PRDM16):c.1627C>T (p.Gln543Ter)Pathogenic
Left ventricular noncompaction cardiomyopathy
β˜…β˜†β˜†β˜†β†’ Residue 543
NM_022114.4(PRDM16):c.2104A>T (p.Lys702Ter)Pathogenic
Left ventricular noncompaction 8|Left ventricular noncompaction cardiomyopathy
β˜…β˜†β˜†β˜†β†’ Residue 702
NM_022114.4(PRDM16):c.2660T>C (p.Leu887Pro)Pathogenic
Cardiomyopathy, dilated, 1LL
β˜†β˜†β˜†β˜†2013β†’ Residue 887
View on ClinVar β†—
Related Genes
CEBPBProtein interaction100%CTBP1Protein interaction97%ADRB3Protein interaction95%BMP7Protein interaction95%CIDEAProtein interaction95%DIO2Protein interaction95%
Tissue Expression6 tissues
Heart
100%
Lung
46%
Ovary
44%
Brain
33%
Liver
7%
Bone Marrow
7%
Gene Interaction Network
Click a node to explore
PRDM16CEBPBCTBP1ADRB3BMP7CIDEADIO2
PROTEIN STRUCTURE
Preparing viewer…
PDB6BW4 Β· 2.00 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.30Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.21 [0.15–0.30]
RankingsWhere PRDM16 stands among ~20K protein-coding genes
  • #4,328of 20,598
    Most Researched110 Β· top quartile
  • #2,397of 5,498
    Most Pathogenic Variants16
  • #1,187of 17,882
    Most Constrained (LOEUF)0.30 Β· top 10%
Genes detectedPRDM16
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis.
PMID: 39549609
Redox Biol Β· 2024
1.00
2
1p36 deletion syndrome: an update.
PMID: 26345236
Appl Clin Genet Β· 2015
0.90
3
PRDM16-dependent antigen-presenting cells induce tolerance to gut antigens.
PMID: 40228524
Nature Β· 2025
0.80
4
ACSS2 controls PPARΞ³ activity homeostasis to potentiate adipose-tissue plasticity.
PMID: 38332049
Cell Death Differ Β· 2024
0.70
5
The browning and mobilization of subcutaneous white adipose tissue supports efficient skin repair.
PMID: 38838641
Cell Metab Β· 2024
0.60